Factor Xa (Coagulation Factor Xa)

Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.

Also Known As:

Networked: 962 relevant articles (73 outcomes, 210 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Becker, Richard C: 29 articles (12/2015 - 05/2002)
2.	Fox, Keith A A: 25 articles (12/2015 - 03/2005)
3.	Mahaffey, Kenneth W: 23 articles (12/2015 - 07/2010)
4.	Piccini, Jonathan P: 21 articles (12/2015 - 07/2010)
5.	Singer, Daniel E: 21 articles (12/2015 - 09/2005)
6.	Hankey, Graeme J: 21 articles (12/2015 - 10/2011)
7.	Patel, Manesh R: 21 articles (12/2015 - 10/2011)
8.	Nessel, Christopher C: 20 articles (12/2015 - 10/2011)
9.	Halperin, Jonathan L: 19 articles (12/2015 - 10/2011)
10.	Berkowitz, Scott D: 17 articles (12/2015 - 12/2010)

Related Diseases

1.	Hemorrhage 09/01/2004 - "Protamine may help to reverse bleeding related to LWMH, although anti-factor Xa activity is not fully normalized by protamine. " 03/19/2014 - "Factor Xa inhibitors were associated with a reduction in major bleeding events, but there was heterogeneity between the included studies, and the reduction was not statistically significant in a prespecified sensitivity analysis." 09/01/2010 - "Some studies have demonstrated elevated anti-factor Xa levels are associated with an increased risk of hemorrhage. " 01/01/2005 - "Data from these trials, although preliminary and based on small numbers of patients, suggest that direct selective Factor Xa inhibition may provide effective anticoagulation, perhaps without excessive bleeding. " 12/17/2015 - "Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. "
2.	Thrombosis (Thrombus) 12/04/2003 - "Inhibition of factor Xa has the potential to provide effective treatment for both venous and arterial thrombosis. " 01/01/2015 - "Efficacy studies included the measurement of thrombus formation, activated partial thromboplastin time, bleeding time, and anti-factor Xa activity; safety studies included the measurement of hemodynamic, hematologic and immunologic parameters. " 02/01/2004 - "After anti-factor Xa and IIa activity pharmacokinetic characterization in healthy volunteers, clinical studies first explored the doses and then confirmed thrombosis prevention effects in postoperative (general and hip or knee replacement surgery) settings as compared with placebo and active treatments. " 11/12/2002 - "Current phase III trials with this synthetic selective factor Xa inhibitor focus on its use in the treatment of patients with venous and arterial thrombosis. " 08/01/2001 - "Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs."
3.	Venous Thromboembolism 06/01/2003 - "Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery." 01/01/2009 - "The results of 3 large randomized trials of activated factor X inhibitors, for the prevention of venous thromboembolism, recently became available. " 08/01/2007 - "A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery." 09/01/2004 - "The aim of this review is to perform a critical analysis of all completed studies evaluating pentasaccharides-synthetically derived, selective inhibitors of activated factor X-in prophylaxis in major orthopedic surgery and the treatment of venous thromboembolism. " 11/15/2003 - "Clinical trials of drugs designed to inhibit factor Xa for the prevention of venous thromboembolism (VTE) after major orthopedic surgery are discussed. "
4.	Venous Thrombosis (Deep-Vein Thrombosis) 11/28/2000 - "The factor Xa inhibitor SR90107a/ORG31540 appears to be an effective and safe treatment for patients with deep vein thrombosis across a wide range of doses. " 08/01/2014 - "Factor Xa inhibitor showed a similar clinical benefit as VKA in the treatment of cerebral venous thrombosis. " 01/15/2013 - "Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis." 06/01/2012 - " is an oral, direct Factor Xa inhibitor that has recently received marketing authorization in the United States for prophylaxis of deep vein thrombosis in patients undergoing hip or knee replacement surgery. " 08/01/2010 - "Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis."
5.	Stroke (Strokes) 09/01/2014 - "Endovascular treatment in acute ischemic stroke patient on factor Xa inhibitor." 03/01/2014 - "Thrombelastography can detect the anticoagulant effect of factor Xa inhibitors in patients with stroke and might be useful in the emergency management of those eligible for thrombolysis." 03/01/2014 - "We sought to determine whether thrombelastography can detect the anticoagulation effect of factor Xa inhibitors in patients with stroke. " 11/01/2011 - "Anticoagulation therapy: Direct factor Xa inhibition improves stroke prevention in patients with AF." 02/01/2003 - "Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats."

Related Drugs and Biologics

1.	rivaroxaban
2.	Thrombin
3.	apixaban
4.	Heparin (Liquaemin)
5.	Warfarin (Coumadin)
6.	Enoxaparin (Lovenox)
7.	Anticoagulants
8.	fondaparinux (Arixtra)
9.	Vitamin K
10.	Aspirin (Acetylsalicylic Acid)

Related Therapies and Procedures

1.	Arthroplasty
2.	Oral Administration
3.	Catheters
4.	Knee Replacement Arthroplasty (Total Knee Replacement)
5.	Hip Replacement Arthroplasty (Total Hip Replacement)